Personalized Antisense Oligonucleotide Therapy for A Single Participant With CHCHD10 ALS
Personalized Antisense Oligonucleotide Therapy for A Single Participant With CHCHD10 ALS
Active, not recruiting · NCT06392126 · Registry updated 2026-07-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Personalized Antisense Oligonucleotide Therapy for A Single Participant With CHCHD10 ALS | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-07-13 | NCT06392126 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Mayo Clinic | 970 |
| n-Lorem Foundation | 18 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Mayo Clinic | Jacksonville | United States | 122 |